<DOC>
	<DOC>NCT02201901</DOC>
	<brief_summary>The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF)/velpatasvir (VEL) fixed dose combination (FDC) with and without ribavirin (RBV) for 12 weeks and SOF/VEL FDC for 24 weeks in adults with chronic hepatitis C virus (HCV) infection and Child-Pugh-Turcotte (CPT) class B cirrhosis.</brief_summary>
	<brief_title>Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Willing and able to provide written informed consent HCV RNA &gt; 10^4 IU/mL at screening Chronic HCV infection (â‰¥ 6 months) Confirmed CPT class B (79) at screening Current or prior history of solid organ transplantation, significant pulmonary disease, significant cardiac disease, or porphyria Inability to exclude hepatocellular carcinoma (HCC) by imaging within 6 months of baseline/Day 1 Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) Screening ECG with clinically significant abnormalities Prior exposure to SOF or any other nucleotide analogue HCV nonstructural protein 5B (NS5B) inhibitor or any HCV NS5A inhibitor Laboratory results outside of acceptable ranges at screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Sofosbuvir</keyword>
	<keyword>Velpatasvir</keyword>
	<keyword>SOF/VEL</keyword>
	<keyword>GS-5816</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>CPT-B</keyword>
</DOC>